talquetamab,belantamab mafodotin
gsk,janssen
['mmsm', 'belantamab', 'talquetamab']
congress | #ash22
ajai chari further detailed that in hard-to-treat patients exposed to prior t-cell redirection therapy, orr with talquetamab was 62.7%, with a similar safety profile to patients naive to t-cell redirection therapy.
#mmsm 
The Multiple Myeloma (MM) Hub is an online educational resource run in collaboration with the European School of Haematology @ESHaematology #mmsm #myeloma